Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Aug;71(8):e31065.
doi: 10.1002/pbc.31065. Epub 2024 May 9.

Isolated central nervous system relapse in two adolescents with primary mediastinal large B-cell lymphoma after treatment with R-DA-EPOCH

Cricket Gullickson  1   2 , Leslie Kersun  3 , Anne Reilly  3 , Alix Seif  3 , Leena Chehab  3
Affiliations
Case Reports

Isolated central nervous system relapse in two adolescents with primary mediastinal large B-cell lymphoma after treatment with R-DA-EPOCH

Cricket Gullickson et al. Pediatr Blood Cancer. 2024 Aug.

Abstract

The addition of rituximab to standard regimens for primary mediastinal large B-cell lymphoma (PMBCL) has significantly improved overall survival. However, the optimal management of isolated central nervous system (CNS) relapse and role of CNS prophylaxis remains undefined. We present cases of two adolescents with PMBCL who developed isolated CNS relapses. While isolated CNS relapse may be managed with high-dose chemotherapy and autologous stem cell transplant with or without CNS radiotherapy, review of these cases and the literature highlight the need for further work to define risk factors for CNS relapse, and identify patients who may benefit from CNS prophylaxis.

Keywords: R‐DA‐EPOCH; central nervous system relapse; primary mediastinal B‐cell lymphoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM. Primary mediastinal large B‐cell lymphoma. Crit Rev Oncol Hematol. 2017;113:318‐327.
    1. Savage KJ. Primary mediastinal large B‐cell lymphoma. Blood. 2022;140(9):955‐970.
    1. Papageorgiou SG, Diamantopoulos P, Levidou G, et al. Isolated central nervous system relapses in primary mediastinal large B‐cell lymphoma after CHOP‐like chemotherapy with or without Rituximab. Hematol Oncol. 2013;31(1):10‐17.
    1. Shah NN, Szabo A, Huntington SF, et al. R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis. Br J Haematol. 2018;180(4):534‐544.
    1. Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open‐label, phase 3 intergroup study. Lancet Oncol. 2019;20(2):216‐228.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources